Pasi Janne

Pasi Janne has defined the landscape of EGFR and ALK compound resistance mutations that emerge under targeted therapy pressure, demonstrating that sequential TKI treatment selects for increasingly complex resistance genotypes including EGFR C797S and compound EGFR/MET/HER2 alterations. His laboratory established that third-generation EGFR inhibitor resistance involves both on-target mutations and bypass pathway activation through MET amplification, HER2 amplification, and small cell transformation. He showed that compound mutations often confer resistance to all available TKIs, necessitating novel therapeutic approaches. His clinical research has guided the development of fourth-generation EGFR inhibitors and combination strategies.